Anyone that asserts that Anavex's pipeline results are tenuous doesn't understand the science or drug trials. This stock has doctors and lab researchers investing in it and I'll take the word of them and Dr George Perry, editor of The Alzheimers Journal, over any anonymous person on social media or AF et al.